AlTi Global Inc. Invests $842,000 in Establishment Labs Holdings Inc. $ESTA

AlTi Global Inc. acquired a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 14,825 shares of the company’s stock, valued at approximately $842,000.

A number of other institutional investors also recently added to or reduced their stakes in ESTA. KBC Group NV purchased a new stake in shares of Establishment Labs during the first quarter valued at about $28,000. Kestra Advisory Services LLC purchased a new stake in Establishment Labs during the fourth quarter valued at approximately $47,000. Quarry LP acquired a new stake in Establishment Labs in the third quarter valued at approximately $34,000. MV Capital Management Inc. purchased a new position in Establishment Labs in the fourth quarter worth $146,000. Finally, Osaic Holdings Inc. grew its holdings in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Trading Up 0.9%

Shares of Establishment Labs stock opened at $93.42 on Tuesday. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The firm has a fifty day moving average price of $80.59 and a 200 day moving average price of $72.12. Establishment Labs Holdings Inc. has a 1 year low of $33.35 and a 1 year high of $94.58. The stock has a market cap of $2.75 billion, a PE ratio of -62.70 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The company had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. During the same period in the prior year, the business posted ($0.70) earnings per share. Establishment Labs’s revenue for the quarter was up 44.7% on a year-over-year basis. Equities research analysts predict that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Insider Activity at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. The trade was a 10.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 255,000 shares of company stock worth $18,144,896. 9.99% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wall Street Zen lowered Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. BTIG Research reiterated a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Citigroup boosted their price objective on shares of Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.43.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.